96 related articles for article (PubMed ID: 21528340)
1. Bioflavonoids, type II [H-3]estradiol binding sites and prostatic cancer cell proliferation.
Markaverich B; Alejandro M
Int J Oncol; 1997 Dec; 11(6):1311-9. PubMed ID: 21528340
[TBL] [Abstract][Full Text] [Related]
2. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
Markaverich BM; Alejandro MA
Int J Oncol; 1998 May; 12(5):1127-35. PubMed ID: 9538139
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
4. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition.
Markaverich BM; Roberts RR; Alejandro MA; Johnson GA; Middleditch BS; Clark JH
J Steroid Biochem; 1988; 30(1-6):71-8. PubMed ID: 3386279
[TBL] [Abstract][Full Text] [Related]
5. Preliminary assessment of luteolin as an affinity ligand for type II estrogen--binding sites in rat uterine nuclear extracts.
Markaverich BM; Gregory RR
Steroids; 1993 Jun; 58(6):268-74. PubMed ID: 8212072
[TBL] [Abstract][Full Text] [Related]
6. Multiple Sites of Type II Site Ligand (Luteolin and BMHPC) Regulation of Gene Expression in PC-3 Cells.
Markaverich BM; Vijjeswarapu M
Int J Biomed Sci; 2012 Dec; 8(4):219-32. PubMed ID: 23675277
[TBL] [Abstract][Full Text] [Related]
7. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
8. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
[TBL] [Abstract][Full Text] [Related]
9. Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth.
Yang F; Song L; Wang H; Wang J; Xu Z; Xing N
PLoS One; 2015; 10(5):e0128277. PubMed ID: 26011145
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo inhibition of nuclear type II estrogen binding sites in the dorsolateral prostate of noble rats.
Ho SM; Viccione T; Yu M
J Steroid Biochem Mol Biol; 1993 Oct; 46(4):489-95. PubMed ID: 8217879
[TBL] [Abstract][Full Text] [Related]
11. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
Wilson MJ; Sinha AA
Anat Rec; 1997 Sep; 249(1):63-73. PubMed ID: 9294650
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.
Miyazawa Y; Sekine Y; Kato H; Furuya Y; Koike H; Suzuki K
Prostate; 2017 Mar; 77(4):337-349. PubMed ID: 27862098
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Chang PL; Juang HH
Int J Cancer; 2012 Jun; 130(12):2812-23. PubMed ID: 21780100
[TBL] [Abstract][Full Text] [Related]
15. [Effect of compound Chinese traditional medicine PC-SPES II in inhibiting proliferation of human prostate cancer cell LNCaP and on expressions of AR and PSA].
Zhang BY; Li YF; Lai Y; Li YS; Chen ZJ
Zhongguo Zhong Yao Za Zhi; 2015 Mar; 40(5):950-6. PubMed ID: 26087562
[TBL] [Abstract][Full Text] [Related]
16. Nuclear type II [3H]estradiol binding sites: a histone H3-H4 complex.
Shoulars K; Rodrigues MA; Crowley JR; Turk J; Thompson T; Markaverich BM
J Steroid Biochem Mol Biol; 2005 Jun; 96(1):19-30. PubMed ID: 15878266
[TBL] [Abstract][Full Text] [Related]
17. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
18. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells.
Dalkin AC; Gilrain JT; Bradshaw D; Myers CE
Endocrinology; 1996 Dec; 137(12):5230-5. PubMed ID: 8940339
[TBL] [Abstract][Full Text] [Related]
19. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
Lau KM; LaSpina M; Long J; Ho SM
Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
[TBL] [Abstract][Full Text] [Related]
20. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
